Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNX-5422 in HER2 Positive Cancers
NCT01848756Phase 2Terminated
- Sponsor
- Esanex, Inc.
- Start
- Apr 2013
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of snx-5422 in breast cancer, Esophagogastric Cancer, urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), sponsored by Esanex, Inc.. Started Apr 2013; status: terminated.
02
Drugs
snx-5422
03
Conditions
breast cancerEsophagogastric Cancerurothelial carcinoma (UC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01848756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01848756.